Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 11/20 | 0.71 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.71 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13960641 | 0.92 | HSP90AA1 (0.70) | HSP90AA1HSP90AB1 | |
| SCHEMBL16628727 | 0.91 | HSP90AA1 (0.71) | HSP90AA1HSP90AB1 | |
| SCHEMBL3076546 | 0.91 | HSP90AA1 (0.69) | HSP90AA1HSP90AB1 | |
| SCHEMBL13180105 | 0.90 | HSP90AA1 (0.73) | HSP90AA1HSP90AB1NAMPT | |
| SCHEMBL27869740 | 0.89 | HSP90AA1 (0.66) | HSP90AA1HSP90AB1NAMPT | |
| SCHEMBL12273440 | 0.89 | HSP90AA1 (0.71) | HSP90AA1HSP90AB1 | |
| SCHEMBL16628749 | 0.89 | HSP90AA1 (0.73) | HSP90AA1HSP90AB1 | |
| SCHEMBL12273815 | 0.89 | HSP90AA1 (0.71) | HSP90AA1HSP90AB1 | |
| SCHEMBL12273502 | 0.88 | HSP90AA1 (0.72) | HSP90AA1HSP90AB1 | |
| SCHEMBL1768003 | 0.87 | HSP90AA1 (0.66) | HSP90AA1HSP90AB1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164833-B1 | Quinazolinamide derivatives useful for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | claimed |
| US-8501754-B2 | Quinazolinamide derivatives | MERCK PATENT GMBH (DE) | 2013-08-06 | — | — | US | claimed |
| US-20100234324-A1 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | claimed |
| EP-2164833-B1 | Quinazolinamide derivatives useful for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234324-A1 | Quinazolinamide derivatives | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885NAMPT 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.